Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

Pfizer Inc. (NYSE:PFE) announced today that the European Commission approved updates to the Summary of Product Characteristics (SmPC) for the company's pneumococcal conjugate vaccine Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), regarding its use in certain populations at high risk of pneumococcal disease.

18 Oct 2013

Scientists identify 127 mutated genes that appear to drive development of tumors in the body

Examining 12 major types of cancer, scientists at Washington University School of Medicine in St. Louis have identified 127 repeatedly mutated genes that appear to drive the development and progression of a range of tumors in the body. The discovery sets the stage for devising new diagnostic tools and more personalized cancer treatments.

17 Oct 2013

UCSD professor receives $6.25M grant to support research on chronic lymphocytic leukemia

The Leukemia & Lymphoma Society has awarded Thomas J. Kipps, MD, PhD, Distinguished Professor of Medicine at the University of California, San Diego School of Medicine, with a 5-year, $6.25 million Specialized Center of Research program grant to support research on chronic lymphocytic leukemia (CLL), the most common adult leukemia in the United States.

16 Oct 2013

Astrazeneca Acquires Spirogen For Up To $440M

...

15 Oct 2013

UC San Diego researcher awarded grant to advance research on chronic lymphocytic leukemia

The Leukemia & Lymphoma Society has awarded Thomas J. Kipps, MD, PhD, Distinguished Professor of Medicine at the University of California, San Diego School of Medicine, with a 5-year, $6.25 million Specialized Center of Research program grant to support research on chronic lymphocytic leukemia, the most common adult leukemia in the United States.

15 Oct 2013

New gene transfer strategy effective for achieving persistent immunotherapy to treat tumors

Cancer immunotherapy can successfully use the body's own immune system to kill tumor cells. But some current approaches to stimulate an antitumor immune response are short-lived, with limited clinical effectiveness. A new gene transfer strategy that introduces modified, immune-stimulating human stem cells is both feasible and effective for achieving persistent immunotherapy to treat leukemias and lymophomas, according to a study published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

11 Oct 2013

Phase 3 study of idelalisibin reports positive results in CLL patients

Following a recommendation by an independent Data Monitoring Committee (DMC), Gilead Sciences, Inc. (Nasdaq:GILD) today announced that its Phase 3 study (Study 116) evaluating idelalisib in previously-treated chronic lymphocytic leukemia (CLL) patients who are not fit for chemotherapy will be stopped early.

10 Oct 2013

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that it has initiated a Phase 2 clinical trial to evaluate PRM-151, its lead product candidate, in patients with myelofibrosis.

10 Oct 2013

ARIAD announces changes in Iclusig product labeling to reflect updated safety information

ARIAD Pharmaceuticals, Inc. today announced results of its review of updated clinical data from the pivotal PACE trial of Iclusig® (ponatinib) and actions that it is taking following consultations with the U.S. Food and Drug Administration (FDA).

9 Oct 2013

Molecular Templates secures $8.5M series C financing plus $10.6M grant from CPRIT

Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of a new class of biologic therapeutics, announced today that it recently secured an $8.5M series C financing led by Excel Venture Management. Santé Ventures, an existing investor, also participated in the round.

9 Oct 2013

New method for improving cord blood transplant success

Starting with a discovery in zebrafish in 2007, Harvard Stem Cell Institute researchers have published initial results of a Phase Ib human clinical trial of a therapeutic that has the potential to improve the success of blood stem cell transplantation.

9 Oct 2013

Two gene alterations pair up to promote growth of leukemia cells

Two gene alterations pair up to promote the growth of leukemia cells and their escape from anti-cancer drugs, according to a study in The Journal of Experimental Medicine.

8 Oct 2013

Kiadis Pharma signs Services Agreement with GRCBDS for Phase II clinical study with ATIR

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that a Services Agreement has been signed with the German Red Cross Blood Donor Service Baden-Wuerttemberg-Hessen (GRCBDS) whereby GRCBDS will provide pharmaceutical development and GMP manufacturing services for Kiadis Pharma's ongoing Phase II clinical study with ATIR™.

7 Oct 2013

Researchers identify protein that triggers inflammation in patients with hemorrhage, sepsis

Investigators at The Feinstein Institute for Medical Research have discovered a protein in the human body that can trigger and mediate inflammation in patients suffering from hemorrhage and sepsis. The findings were published in the online version of Nature Medicine on October 6, 2013.

7 Oct 2013

New therapeutic targets and drugs may benefit people with leukemia

An Indiana University cancer researcher and his colleagues have discovered new therapeutic targets and drugs that may someday benefit people with certain types of leukemia or blood cancer.

5 Oct 2013

Active ingredient of ipecac syrup inhibits growth of cancer cells

An old home remedy called ipecac syrup, once stocked in medicine cabinets in case of accidental poisoning, is showing promise as a new chemotherapy drug for bladder cancer.

4 Oct 2013

NYU researchers receive $6.25M grant for pioneering research into acute lymphoblastic leukemia

Researchers at The Cancer Institute at NYU Langone Medical Center is leading a $6.25 million, five-year research initiative, funded by the Leukemia & Lymphoma Society, to develop new therapies and advance the cure rate for children and young adults with acute lymphoblastic cancer (ALL), the most common form of childhood cancer.

4 Oct 2013

Research reveals significant role of Axl receptor in progression, therapeutic resistance of AML

BerGenBio AS, an oncology biopharmaceutical company, announces that a paper entitled "Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine cross-talk of leukemia cells with bone marrow stroma" by Ben-Batalla et al., has been published in Blood, the most cited peer-reviewed research journal in the field of hematology.

1 Oct 2013

Standoff between a mutated gene and normal counterpart keeps certain cancer cells alive

What keeps leukemia cells alive almost forever, able to continue dividing endlessly and aggressively? New research at the Weizmann Institute suggests that, in around a quarter of all leukemias, the cancer cells rely on an internal "balance of terror" to keep going.

1 Oct 2013

Leukemia News and Research

Further Reading

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

Scientists identify 127 mutated genes that appear to drive development of tumors in the body

UCSD professor receives $6.25M grant to support research on chronic lymphocytic leukemia

Astrazeneca Acquires Spirogen For Up To $440M

UC San Diego researcher awarded grant to advance research on chronic lymphocytic leukemia

New gene transfer strategy effective for achieving persistent immunotherapy to treat tumors

Phase 3 study of idelalisibin reports positive results in CLL patients

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

ARIAD announces changes in Iclusig product labeling to reflect updated safety information

Molecular Templates secures $8.5M series C financing plus $10.6M grant from CPRIT

New method for improving cord blood transplant success

Two gene alterations pair up to promote growth of leukemia cells

Kiadis Pharma signs Services Agreement with GRCBDS for Phase II clinical study with ATIR

Researchers identify protein that triggers inflammation in patients with hemorrhage, sepsis

New therapeutic targets and drugs may benefit people with leukemia

Active ingredient of ipecac syrup inhibits growth of cancer cells

NYU researchers receive $6.25M grant for pioneering research into acute lymphoblastic leukemia

Research reveals significant role of Axl receptor in progression, therapeutic resistance of AML

Standoff between a mutated gene and normal counterpart keeps certain cancer cells alive

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News